European Commission Grants Orphan Drug Designation to Florbetaben for Diagnosis of ATTR Amyloidosis

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent for the management of amyloid light chain (AL) amyloidosis in both the EU and USThe efficacy of florbetaben (18F) in diagnosing cardiac amyloidosis is being evaluated in an ongoing multi-center Phase 3 studyView original content:https://www.prnewswire.co.uk/news-releases/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-diagnosis-of-attr-amyloidosis-302480425.html